OTLK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications...

Stats
Šios dienos apimtis	201 543
Vidutinė apimtis	659 643
Rinkos kapitalizacija	183.47M
EPS	$0 ( 2024-02-13 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.12
ATR14	$0.0160 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Syntone Ventures Llc	Buy	714 286	Common Stock
2024-04-15	Syntone Ventures Llc	Buy	1 071 429	Warrant (Right to Buy)
2024-03-28	Haddadin Yezan Munther	Buy	1 882	Common Stock
2024-03-20	Trenary C Russell Iii	Buy	455 000	Stock Option (Right to Buy)
2024-03-20	Evanson Jeff	Buy	25 000	Stock Option (Right to Buy)

INSIDER POWER
91.54
Last 99 transactions
Buy: 132 469 020 \| Sell: 31 433 684

Tūris Koreliacija

Ilgas: -0.28 (neutral)

Trumpas: -0.38 (neutral)

Signal:(52.182) Neutral

Outlook Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Outlook Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.11
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.70
( moderate )

0.25
( neutral )

Outlook Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-44 188.00 (0.00 %)
EPS:	$-4.72

FY	2023
Pajamos:	$0
Bruto pelnas:	$-44 188.00 (0.00 %)
EPS:	$-4.72

FY	2022
Pajamos:	$0
Bruto pelnas:	$-204 694 (0.00 %)
EPS:	$-6.23

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.